1. In Vivo

Value-Based Medtech Rides The Money-Go-Round Into 2016

 
• By Ashley Yeo

The M&A bonanza for companies in the medtech sector continued into 2015 and there is no end in sight in 2016 as manufacturers seek to augment and fine-tune portfolios to meet the new demands of payers and providers. Longer term, there are signs of a change in the top global medtech rankings.

The technology-driven medical device industry: that’s so 2014. The 2016 medtech executive has other things on his/her mind, and they all come under the general job title of “value-based health care delivery chain partner.” Titles are not as simple as they once were, and while no one yet wears that precise title on his/her lapel badge (come to that, lapels are not what they once were), medtech companies in the 2010s know they are playing in a totally different arena and are part of an industry in transformation.

This has happened due to the convergence of several factors related to provider/payer cost savings, rising demand for care, a...

More from Deal-Making

More from In Vivo

Deals In Depth: June 2025

 
• By Deanna Kamienski and Maureen Riordan

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.